Tomoki Makino

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 16

Top Venues

British journal of cancer

Esophagus : official journal of the Japan Esophageal Society

Annals of gastroenterological surgery

International journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Tomoki Makino, Shigeto Nakai, Kota Momose, Kotaro Yamashita, Koji Tanaka, Hiroshi Miyata, Sachiko Yamamoto, Masaaki Motoori, Yutaka Kimura, Yuki Ushimaru, Motohiro Hirao, Jin Matsuyama, Yusuke Akamaru, Yukinori Kurokawa, Hidetoshi Eguchi, Yuichiro Doki
Efficacy and survival of nivolumab treatment for recurrent/unresectable esophageal squamous-cell carcinoma: real-world clinical data from a large multi-institutional cohort. Esophagus : official journal of the Japan Esophageal Society 21 (3) (2024)
Tomoki Makino, Shigeto Nakai, Kota Momose, Kotaro Yamashita, Koji Tanaka, Hiroshi Miyata, Sachiko Yamamoto, Masaaki Motoori, Yutaka Kimura, Yuki Ushimaru, Motohiro Hirao, Jin Matsuyama, Yusuke Akamaru, Yukinori Kurokawa, Hidetoshi Eguchi, Yuichiro Doki
Efficacy and survival of nivolumab treatment for recurrent/unresectable esophageal squamous-cell carcinoma: real-world clinical data from a large multi-institutional cohort. Esophagus : official journal of the Japan Esophageal Society (2024)
Tomoki Makino, Shigeto Nakai, Kota Momose, Kotaro Yamashita, Koji Tanaka, Hiroshi Miyata, Sachiko Yamamoto, Masaaki Motoori, Yutaka Kimura, Yuki Ushimaru, Motohiro Hirao, Jin Matsuyama, Yusuke Akamaru, Yukinori Kurokawa, Hidetoshi Eguchi, Yuichiro Doki
Efficacy and survival of nivolumab treatment for recurrent/unresectable esophageal squamous-cell carcinoma: real-world clinical data from a large multi-institutional cohort. Esophagus : official journal of the Japan Esophageal Society 21 (3) (2024)
Tomoki Makino, Shigeto Nakai, Kota Momose, Kotaro Yamashita, Koji Tanaka, Hiroshi Miyata, Sachiko Yamamoto, Masaaki Motoori, Yutaka Kimura, Yuki Ushimaru, Motohiro Hirao, Jin Matsuyama, Yusuke Akamaru, Yukinori Kurokawa, Hidetoshi Eguchi, Yuichiro Doki
Efficacy and survival of nivolumab treatment for recurrent/unresectable esophageal squamous-cell carcinoma: real-world clinical data from a large multi-institutional cohort. Esophagus : official journal of the Japan Esophageal Society 21 (3) (2024)
Ryugo Teranishi, Tsuyoshi Takahashi, Yuuki Obata, Toshirou Nishida, Shuichi Ohkubo, Hiromi Kazuno, Yurina Saito, Satoshi Serada, Minoru Fujimoto, Yukinori Kurokawa, Takuro Saito, Kazuyoshi Yamamoto, Kotaro Yamashita, Koji Tanaka, Tomoki Makino, Kiyokazu Nakajima, Seiichi Hirota, Tetsuji Naka, Hidetoshi Eguchi, Yuichiro Doki
Combination of pimitespib (TAS-116) with sunitinib is an effective therapy for imatinib-resistant gastrointestinal stromal tumors. International journal of cancer (2023)
Yoshinori Hayashi, Tomoki Makino, Eiichi Sato, Kenji Ohshima, Yuya Nogi, Takashi Kanemura, Keiichiro Honma, Kotaro Yamashita, Takuro Saito, Koji Tanaka, Kazuyoshi Yamamoto, Tsuyoshi Takahashi, Yukinori Kurokawa, Hiroshi Miyata, Kiyokazu Nakajima, Hisashi Wada, Eiichi Morii, Hidetoshi Eguchi, Yuichiro Doki
Density and maturity of peritumoral tertiary lymphoid structures in oesophageal squamous cell carcinoma predicts patient survival and response to immune checkpoint inhibitors. British journal of cancer (2023)
Yohei Nose, Tomoki Makino, Mitsuaki Tatsumi, Koji Tanaka, Kotaro Yamashita, Toshiki Noma, Takuro Saito, Kazuyoshi Yamamoto, Tsuyoshi Takahashi, Yukinori Kurokawa, Kiyokazu Nakajima, Hidetoshi Eguchi, Yuichiro Doki
Risk stratification of oesophageal squamous cell carcinoma using change in total lesion glycolysis and number of PET-positive lymph nodes. British journal of cancer (2023)
Makoto Yamasaki, Hiroshi Miyata, Kotaro Yamashita, Takuya Hamakawa, Koji Tanaka, Keijiro Sugimura, Tomoki Makino, Atsushi Takeno, Osamu Shiraishi, Masaaki Motoori, Yutaka Kimura, Motohiro Hirao, Kazumasa Fujitani, Takusi Yasuda, Masahiko Yano, Hidetoshi Eguchi, Yuichiro Doki
Chemoradiotherapy versus triplet chemotherapy as initial therapy for T4b esophageal cancer: survival results from a multicenter randomized Phase 2 trial. British journal of cancer (2023)
Ryugo Teranishi, Tsuyoshi Takahashi, Yuuki Obata, Toshirou Nishida, Shuichi Ohkubo, Hiromi Kazuno, Yurina Saito, Satoshi Serada, Minoru Fujimoto, Yukinori Kurokawa, Takuro Saito, Kazuyoshi Yamamoto, Kotaro Yamashita, Koji Tanaka, Tomoki Makino, Kiyokazu Nakajima, Seiichi Hirota, Tetsuji Naka, Hidetoshi Eguchi, Yuichiro Doki
Combination of pimitespib (TAS-116) with sunitinib is an effective therapy for imatinib-resistant gastrointestinal stromal tumors. International journal of cancer (2023)
Tomoki Makino, Makoto Yamasaki, Koji Tanaka, Kotaro Yamashita, Shinya Urakawa, Tomo Ishida, Osamu Shiraishi, Keijiro Sugimura, Hiroshi Miyata, Masaaki Motoori, Kazumasa Fujitani, Atsushi Takeno, Motohiro Hirao, Yutaka Kimura, Taroh Satoh, Masahiko Yano, Hidetoshi Eguchi, Yuichiro Doki, Takushi Yasuda
Multicenter randomised trial of two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for locally advanced oesophageal squamous cell carcinoma. British journal of cancer 126 (11) (2022)
Tomo Ishida, Tsuyoshi Takahashi, Yukinori Kurokawa, Toshirou Nishida, Seiichi Hirota, Satoshi Serada, Minoru Fujimoto, Tetsuji Naka, Ryugo Teranishi, Takuro Saito, Kotaro Yamashita, Koji Tanaka, Kazuyoshi Yamamoto, Tomoki Makino, Makoto Yamasaki, Kiyokazu Nakajima, Hidetoshi Eguchi, Yuichiro Doki
Targeted therapy for drug-tolerant persister cells after imatinib treatment for gastrointestinal stromal tumours. British journal of cancer 125 (11) (2021)
Osamu Shiraishi, Tomoki Makino, Makoto Yamasaki, Koji Tanaka, Kotaro Yamashita, Tomo Ishida, Keijiro Sugimura, Hiroshi Miyata, Masaaki Motoori, Kazumasa Fujitani, Atsushi Takeno, Motohiro Hirao, Yutaka Kimura, Taroh Satoh, Masahiko Yano, Yuichiro Doki, Takushi Yasuda
Two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for treating locally advanced esophageal cancer: short-term outcomes of a multicenter randomized phase II trial. Esophagus : official journal of the Japan Esophageal Society 18 (4) (2021)
Teruyuki Kobayashi, Tomoki Makino, Kotaro Yamashita, Takuro Saito, Koji Tanaka, Tsuyoshi Takahashi, Yukinori Kurokawa, Makoto Yamasaki, Kiyokazu Nakajima, Eiichi Morii, Hidetoshi Eguchi, Yuichiro Doki
APR-246 induces apoptosis and enhances chemo-sensitivity via activation of ROS and TAp73-Noxa signal in oesophageal squamous cell cancer with TP53 missense mutation. British journal of cancer 125 (11) (2021)
Kei Yamamoto, Tomoki Makino, Eiichi Sato, Toshiki Noma, Shinya Urakawa, Tomohira Takeoka, Kotaro Yamashita, Takuro Saito, Koji Tanaka, Tsuyoshi Takahashi, Yukinori Kurokawa, Makoto Yamasaki, Kiyokazu Nakajima, Masaki Mori, Yuichiro Doki, Hisashi Wada
Tumor-infiltrating M2 macrophage in pretreatment biopsy sample predicts response to chemotherapy and survival in esophageal cancer. Cancer science 111 (4) (2020)
Keijiro Sugimura, Makoto Yamasaki, Takushi Yasuda, Masahiko Yano, Motohiro Hirao, Kazumasa Fujitani, Yutaka Kimura, Hiroshi Miyata, Masaaki Motoori, Atsushi Takeno, Osamu Shiraishi, Tomoki Makino, Takayuki Kii, Koji Tanaka, Taro Satoh, Masaki Mori, Yuichiro Doki
Long-term results of a randomized controlled trial comparing neoadjuvant Adriamycin, cisplatin, and 5-fluorouracil vs docetaxel, cisplatin, and 5-fluorouracil followed by surgery for esophageal cancer (OGSG1003). Annals of gastroenterological surgery 5 (1) (2020)
Tomoki Makino, Makoto Yamasaki, Koji Tanaka, Yasuhiro Miyazaki, Tsuyoshi Takahashi, Yukinori Kurokawa, Masaaki Motoori, Yutaka Kimura, Kiyokazu Nakajima, Masaki Mori, Yuichiro Doki
Treatment and clinical outcome of clinical T4 esophageal cancer: A systematic review. Annals of gastroenterological surgery 3 (2) (2018)

Tomoki Makino.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Tomoki Makino